Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine

Journal of Hepatology

Volumn 32, Issue 2, 2000, Pages 300-306

  Santantonio, Teresa ^a   Mazzola, Michele ^b   Iacovazzi, Tiziana ^b   Miglietta, Antonio ^b   Guastadisegni, Angela ^b   Pastore, Giuseppe ^b  

^a Teresa Santantonio   (Italy)

^b NONE

Author keywords

Anti HBe positive chronic hepatitis B; Antiviral therapy; Lamivudine; Lamivudine resistant mutants

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; AMINO ACID; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LAMIVUDINE; VIRUS DNA;

ABDOMINAL PAIN; ADULT; AMINO ACID SEQUENCE; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESISTANCE; FATIGUE; FEMALE; FOLLOW UP; GENE AMPLIFICATION; HEADACHE; HEPATITIS B; HUMAN; LONG TERM CARE; MALE; PRIORITY JOURNAL; PRURITUS; RELAPSE; VIRUS INHIBITION;

EID: 0033983646     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(00)80076-8     Document Type: Article

References (28)

1. Hadziyannis SJ. Hepatitis B e antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. Viral Hep Rev. 1:1995;7-36.
2. Brunetto MR, Giarin E, Oliveri F, Chiaberge E, Baldi M, Alfarano A, et al. Wild-type and e antigen-deficient hepatitis B viruses and course of chronic hepatitis B. Proc Natl Acad Sci USA. 88:1991;4186-4190.
3. Naoumov NV, Schneider R, Groetzinger T, Jung MC, Miska S, Pape GR, et al. Precore mutant hepatitis B virus infection and liver disease. Gastroenterology. 102:1992;538-543.
4. Santantonio T, Jung MC, Miska S, Pastore G, Pape GR, Will H. Prevalence and type of pre-C HBV mutants in anti-HBe positive carriers with chronic liver disease in a highly endemic area. Virology. 183:1991;840-844.
5. Brunetto MR, Olivieri F, Rocca G, Griscuolo D, Chiaberge E, Capalbo M, et al. Natural course and response to interferon of chronic hepatitis B accompanied by antibodies to hepatitis B e antigen. Hepatology. 10:1989;198-202.
6. Hadziyannis S, Bramou T, Makris A, Moussoulis G, Zignego L, Papaioannou C. Interferon alfa-2b treatment of HBeAg negative/serum HBV-DNA positive chronic active hepatitis type B. J Hepatol. 11:1990;S133-S136.
7. Pastore G, Santantonio T, Milella M, Mariano N, Moschetta R, Pollice L. Anti-HBe positive chronic hepatitis B with HBV-DNA in the serum: response to a six month course of lymphoblastoid interferon. J Hepatol. 14:1992;221-225.
8. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med. 333:1995;1657-1661.
9. Lai C-L, Ching C-K, Tung AK-M, Li E, Young J, Hill A, et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology. 25:1997;241-244.
10. Lai C-L, Chien R-N, Leung NWY, Chang T-T, Guan R, Tai D-I, et al. A one year trial of lamivudine for chronic hepatitis B. N Engl J Med. 339:1998;61-68.
11. Honkoop-P, de-Man RA, Zondervan PE, Schalm SW. Histological improvement in patients with chronic hepatitis B virus infection treated with lamivudine. Liver. 17:1997;103-106.
12. Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology. 28:1998;585-589.
13. Andreone P, Caraceni P, Grazi GL, Belli L, Milandri GL, Ercolani G, et al. Lamivudine treatment for acute hepatitis B after liver transplantation. J Hepatol. 29:1998;985-989.
14. Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin R, et al. Efficacy of lamivudine in patients with HBeAg negative/HBV DNA positive (pre-core mutant) chronic hepatitis B. Hepatology. 29:1999;939-945.
15. Nevens F, Main J, Honkoop P, Tyrrell DL, Barber J, Sullivan MT, et al. Lamivudine therapy for chronic hepatitis B: a six month randomized dose-ranging study. Gastroenterology. 113:1997;1258-1263.
16. Honkoop P, de Man RA, Niesters HGM, Main J, Nevens F, Thomas HC, et al. Quantitative hepatitis B virus DNA assessment by the limiting-dilution polymerase chain reaction in chronic hepatitis B patients: evidence of continuing viral suppression with longer duration and higher dose of lamivudine therapy. J Viral Hepat. 5:1998;307-312.
17. Benhamou Y, Katlama C, Lunel F, Coutellier A, Dohin E, Hamm N, et al. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med. 125:1996;705-712.
18. Dienstag JL, Schiff ER, Mitchell M, Gitlin N, Lisoos T, Condreay L, et al. Extending lamivudine retreatment for chronic hepatitis B. [abstract] Hepatology. 24:1996;188.
19. Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest. 102:1998;968-975.
20. Zeuzem S, de Man RA, Honkoop P, Kurt Roth W, Schalm SW, Schmidt JM. Dynamics of hepatitis B virus infection in vivo. J Hepatol. 27:1997;431-436.
21. Nowak MA, Bonhoeffer S, Hill AM, Boheme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA. 93:1996;4398-4402.
22. Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology. 24:1996;711-713.
23. Honkoop P, Niesters HG, de Man RA, Osterhaus AD, Schalm SW. Lamivudine resistance in immunocompetent chronic hepatitis B. J Hepatol. 26:1997;1393-1395.
24. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology. 27:1998;1670-1677.
25. Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology. 27:1998;628-633.
26. Zoulim F, Trépo C. Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy. J Hepatol. 29:1998;151-168.
27. Honkoop P, de Man RA, Niesters HGM, Schalm SW. Clinical impact of lamivudine resisatance in chronic hepatitis B. J Hepatol. 29:1998;510-511.
28. Chayama K, Suzuki Y, Kobayashi M, Kobayashi M, Tsubota A, Hashimoto M, et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology. 27:1998;1711-1716.